Clinical benefit of R-CHOP without splenectomy in stage i primary splenic diffuse large B-cell lymphoma

Tara Rajendran, Jyoti Ramanath Kini, Aysha Abna, Krishna Prasad

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

Primary splenic diffuse large B-cell lymphoma (PS-DLBCL) is a relatively rare malignancy, and there are no optimal approaches for diagnosis and management. There are less invasive splenic biopsies that effectively obviate diagnostic and elective splenectomies. We report a man in his 50s with 2-day history of pain in the abdomen and who was found to have a splenic mass on PET-CT. A CT-guided core needle splenic biopsy confirmed the diagnosis of PS-DLBCL. He was managed with six cycles of R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) alone, without splenectomy. The patient attained complete remission, and he is disease free at 6 years of follow-up.

Original languageEnglish
Article numbere246610
JournalBMJ Case Reports
Volume15
Issue number1
DOIs
Publication statusPublished - 04-01-2022

All Science Journal Classification (ASJC) codes

  • General Medicine

Fingerprint

Dive into the research topics of 'Clinical benefit of R-CHOP without splenectomy in stage i primary splenic diffuse large B-cell lymphoma'. Together they form a unique fingerprint.

Cite this